GSA Capital Partners LLP Has $56,000 Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET)

GSA Capital Partners LLP grew its holdings in Adicet Bio, Inc. (NASDAQ:ACET) by 161.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 39,208 shares of the company’s stock after purchasing an additional 24,203 shares during the period. GSA Capital Partners LLP’s holdings in Adicet Bio were worth $56,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ACET. Castleview Partners LLC acquired a new stake in Adicet Bio in the third quarter valued at about $75,000. Point72 DIFC Ltd lifted its holdings in shares of Adicet Bio by 77.5% in the second quarter. Point72 DIFC Ltd now owns 33,441 shares of the company’s stock worth $40,000 after acquiring an additional 14,596 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of Adicet Bio by 790.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 409,049 shares of the company’s stock valued at $495,000 after purchasing an additional 363,095 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Adicet Bio during the 2nd quarter valued at approximately $62,000. Finally, Stonepine Capital Management LLC increased its position in Adicet Bio by 330.6% during the 2nd quarter. Stonepine Capital Management LLC now owns 609,446 shares of the company’s stock worth $737,000 after purchasing an additional 467,898 shares in the last quarter. Institutional investors and hedge funds own 83.89% of the company’s stock.

Adicet Bio Stock Performance

Shares of ACET opened at $0.90 on Tuesday. The stock’s 50-day moving average price is $1.32 and its two-hundred day moving average price is $1.38. Adicet Bio, Inc. has a 12 month low of $0.89 and a 12 month high of $3.77. The company has a market capitalization of $74.49 million, a PE ratio of -0.53 and a beta of 1.81.

Adicet Bio (NASDAQ:ACET) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.34). Equities research analysts predict that Adicet Bio, Inc. will post -1.39 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on ACET shares. Guggenheim initiated coverage on shares of Adicet Bio in a report on Monday, September 30th. They set a “buy” rating and a $7.00 price target for the company. StockNews.com cut Adicet Bio from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. HC Wainwright reissued a “neutral” rating on shares of Adicet Bio in a research note on Monday, November 18th. Wedbush restated an “outperform” rating and set a $5.00 price target on shares of Adicet Bio in a report on Thursday, November 7th. Finally, Canaccord Genuity Group dropped their price objective on shares of Adicet Bio from $19.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $7.50.

About Adicet Bio

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.